Secondary acute myelogenous leukemia following safe exposure to etoposide
العنوان: | Secondary acute myelogenous leukemia following safe exposure to etoposide |
---|---|
المؤلفون: | Kimo C. Stine, David L. Becton, R L Saylors, J R Sawyer |
المصدر: | Journal of Clinical Oncology. 15:1583-1586 |
بيانات النشر: | American Society of Clinical Oncology (ASCO), 1997. |
سنة النشر: | 1997 |
مصطلحات موضوعية: | Cancer Research, Chemotherapy, medicine.medical_specialty, Vincristine, business.industry, medicine.medical_treatment, Bleomycin, medicine.disease, Gastroenterology, Surgery, Lymphoma, Radiation therapy, chemistry.chemical_compound, Histiocytosis, Oncology, chemistry, Internal medicine, Medicine, business, Complication, Etoposide, medicine.drug |
الوصف: | PURPOSE To present two patients as illustrations of the risk of developing secondary acute myelogenous leukemia (sAML) when theoretically safe doses of etoposide (VP-16) are used. PATIENTS AND METHODS Patient no. 1 was a 15-year-old white girl diagnosed with stage IIa Hodgkin's disease. She was treated with a combination of vincristine, doxorubicin, bleomycin, and VP-16 (2 g/m2 total) over 4 months, followed by 25.5 Gy of involved-field radiotherapy. Patient no. 2 was an 11-year-old white boy diagnosed with virus-associated hemophagocytic syndrome (VAHS). He was treated with VP-16 intravenously (IV) and orally (0.3 g and 2.8 g/m2, respectively). RESULTS Patient no. 1 developed AML 16 months from the diagnosis of Hodgkin's disease. Patient no. 2 developed AML 26 months from diagnosis. Both bone marrows were consistent with French-American-British (FAB) M4 disease. Both patients had abnormalities of the long arm of chromosome 11. CONCLUSION The use of low-dose or oral VP-16 can be associated with the development of sAML. Clinicians should be cautious in the use of VP-16 in low-risk diseases. |
تدمد: | 1527-7755 0732-183X |
DOI: | 10.1200/jco.1997.15.4.1583 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::1bf1748fd6de04499b49a03430e859f9 https://doi.org/10.1200/jco.1997.15.4.1583 |
رقم الانضمام: | edsair.doi...........1bf1748fd6de04499b49a03430e859f9 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 15277755 0732183X |
---|---|
DOI: | 10.1200/jco.1997.15.4.1583 |